Jul 2026· Journal of surgical sciences· 0 citations· 21 references
TL;DR
Longer symptom duration was associated with larger tumor size, and larger tumor size was significantly associated with nodal positivity, highlighting the importance of early diagnosis, timely referral, and breast cancer awareness programs to improve clinical outcomes.
Abstract
Introduction: Breast cancer is the most common malignancy among women worldwide and represents an increasing oncological burden in Bangladesh. Delayed presentation, limited screening facilities, and heterogeneity in tumor biology continue to influence treatment outcomes in low- and middle-income countries. This study aimed to evaluate the clinicopathological profile, molecular subtypes, treatment patterns, and short-term outcomes of breast cancer patients treated at a tertiary care teaching hospital in Bangladesh.
Methodology: This retrospective observational study was conducted in the Department of Surgery, Anwar Khan Modern Medical College Hospital, Dhaka, Bangladesh. Histopathological confirmed breast cancer patients treated between January 2022 and June 2023 were included in the analysis.
Results: A total of 43 patients were analyzed. The median tumor size was 3.0 cm (IQR: 2.0–4.0 cm), and the median symptom duration was 4.0 months (IQR: 2.0–6.0 months). ER/PR-positive, HER2- negative tumors constituted the most common molecular subtype. Tumor size greater than 2 cm was significantly associated with nodal positivity (OR 9.14, 95% CI 1.53–54.54; p=0.020). Tumor size demonstrated a significant positive correlation with the number of involved lymph nodes (rho=0.62, p<0.001). Symptom duration was also positively correlated with tumor size (rho=0.60, p<0.001).
Conclusion: Breast cancer patients in Bangladesh continue to present with relatively advanced disease. Longer symptom duration was associated with larger tumor size, and larger tumor size was significantly associated with nodal positivity, highlighting the importance of early diagnosis, timely referral, and breast cancer awareness programs to improve clinical outcomes.
Journal of Surgical Sciences 2024;28(2): 77-84
Bangladeshi women with breast cancer frequently present at a younger age and advanced stage, with a substantial proportion of aggressive molecular subtypes, highlighting the need for early detection strategies and subtype-guided management in tertiary care settings.
Rana Jahangir Alam, Md. Saiful Islam, Iftakhar Al Mamun et al.· Journal of surgical sciences· 0 citations
Lung cancer patients attending Nobel Medical College Teaching Hospital predominantly presented at advanced stages, and adenocarcinoma was the leading histological subtype.
Pradip Bhandari· Journal of Nobel Medical Col...· 0 citations
The findings highlight the importance of early detection, timely surgical intervention, and multimodal adjuvant therapy in improving outcomes among breast carcinoma patients.
Dr. Siddharth Shukla, Dr. Yogeshwar P Shukla, Dr. Krishnanand et al.· Asian Journal of Medical Res...· 0 citations
Background: Endometrial carcinoma is a significant contributor to the global female cancer burden. Its incidence in India is rising because of increasing life expectancy and metabolic risk factors, although Indian outcome data remain limited. This study aimed to evaluate the spectrum of uterine malignancies and assess their oncological outcomes in an Indian cohort.
Methods: This prospective observational study was conducted at a tertiary care centre over a five-year period (2020–2025). Seventy (70) women were included following histopathological confirmation of uterine malignancy. Data on clinical presentation, histological subtype, staging, treatment, and outcomes were recorded and analysed using descriptive statistics.
Results: The mean age was in the sixth decade, with 88.6% of patients being postmenopausal. Endometrioid adenocarcinoma was the most common histological subtype (75.7%), followed by serous carcinoma (7.1%), carcinosarcoma (4.3%), and clear cell carcinoma (4.3%). Most patients presented at FIGO Stage I (61.5%) and underwent primary surgical management. Adjuvant therapy was administered in 32.9% of cases based on stage and risk factors. At a median follow-up, 72.9% of patients were alive and recurrence was observed in only 1.4%. Binary logistic regression showed that none of the individual pathological factor’s tumour grade, histology, LVSI, myometrial invasion, or cervical stromal involvement significantly predicted lymph node involvement.
Conclusion: Endometrioid carcinoma remains the predominant uterine malignancy in Indian women, typically presenting in postmenopausal women at an early stage with favourable outcomes. Given the inability of conventional pathological risk factors to reliably predict nodal involvement, comprehensive surgical staging using sentinel lymph node mapping or systematic lymphadenectomy should be considered in all cases, irrespective of initial stage.
Dinesh Kumar, G. Yadav, Pratibha Singh et al.· International Journal of Rep...· 0 citations
Cervical cancer disproportionately affects low- and middle-income countries, yet real-world treatment data from many regions remain scarce. We aimed to describe treatment patterns, disease burden, and survival outcomes in patients with advanced cervical cancer treated at Armenia's national referral centre.
We conducted a retrospective cohort study of consecutive patients with advanced cervical cancer who received paclitaxel-platinum chemotherapy at the national oncology centre between January 2008 and August 2024. Treatment response was assessed clinically and radiologically after the first chemotherapy course. Overall survival was estimated using the Kaplan-Meier method with 95% confidence intervals. Temporal trends were examined across three treatment eras.
A total of 159 patients were included (mean age 51.7 ± 10.2 years). The majority presented with advanced disease: 87.9% had International Federation of Gynaecology and Obstetrics (FIGO) stage III–IV, and 57.2% had distant metastases. Treatment regimens included paclitaxel-carboplatin (63.5%) and paclitaxel-cisplatin (35.2%); 38.4% received bevacizumab. The overall response rate was 48.4%, and the disease control rate was 64.2%. Median overall survival was 36.0 months (95% CI: 26.0–56.0). Bevacizumab use varied across eras (35.7% in 2008–2014, 20.0% in 2015–2018, and 53.2% in 2019–2024), whilst stage III–IV presentation increased from 78.6% in 2008–2014 to 91.0% in 2019–2024.
Despite late-stage presentation typical of low- and middle-income countries, survival outcomes were broadly consistent with international real-world data. The rising proportion of advanced-stage disease highlights the urgent need for improved screening programmes.
A. Tadevosyan, Gagik Jilavyan, Evelina Bakhshinyan et al.· South Asian Journal of Cance...· 0 citations
Thyroid cancer is considered the most common endocrine tumor worldwide and its incidence is increasing. We conducted this study to analyses demographic, clinicopathological, imaging data, treatment, outcomes, recurrence rate, overall survival and prognosis of differentiated thyroid cancer (DTC) cases. This is a retrospective study done in our tertiary hospital including patients diagnosed with DTC from 2015 to 2020. One hundred seventy-six patients’ data were reviewed including full detailed history, thyroid and lymph node assessment, radiology results, preoperative staging, surgical modalities, histopathological diagnosis, postoperative risk stratification, radioactive iodine ablation therapy and outcomes including recurrence, overall survival, disease free survival. Mean age of the studied patients was 42.74 ± 12.19 years old. Most of the studied patients were females representing 84.1% meanwhile males represented 15.9%. There were 147 in stage I (83.5%), 22 in stage II (12.5%), 5 patients in stage III (2.8%) and 2 in stage IV (1.1%). Near half of the studied patients underwent neck dissection. Most of the studied patients received postoperative radioactive iodine (RAI). 9.1% of the treated patients had nodal recurrence. Patients with recurrence were significantly older than non-recurrence patients. Recurrence is significantly more in old and male patients and with positive lymph nodes involvement. Most of the pathological parameters were not significantly related to recurrence with exception of capsular invasion which showed significant correlation with recurrence. 5-year survival was 95.9%. 5 years disease free survival was 85.1%. Patient age, lymph node metastases, capsular invasion, and tumor size were the most important prognostic factors in relation to recurrence rate, while the roles of tumor multifocality and lymphovascular invasion were insignificant.
S. Ibrahim, Ahmed Adly Mohammed, Mohammed Naguib Mohamed et al.· The Egyptian Journal of Otol...· 0 citations